Skip to main content
Caplight Logo









Remidose Aerosols Inc.

Remidose Aerosols Inc.

Private
StratfordHealthcare & Life Scienceshttps://www.remidose.com/

Last Round

Accelerator

Aug 27, 2021

Total Funding Raised

$60,000

Company Overview

Remidose Aerosols Inc. is a cannabis company that manufactures medical devices and cannabis-based products, including metered-dose inhalers and topical formulations.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

metered-dose inhalercannabis delivery deviceprecision dosingcannabis oilmedical cannabisvape techcannabis techdrug delivery technologyoral spraycannabis licensingIP licensingtopical formulationcannabis processorroyalty model

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Remidose Aerosols Inc. Comparables

Compare Remidose Aerosols Inc. with similar companies based on industry and business-model similarity.

Remidose Aerosols Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Syqe Medical
78%
Roxx Labs
75%
Medipharm Labs Corp
72%

Remidose Aerosols Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorAug 27, 2021
GrantJul 26, 2021
GrantDec 18, 2020

Remidose Aerosols Inc. Investors

Notable investors and investment history

Remidose Aerosols Inc. investors
InvestorRounds
Atlantic Canada Opportunities AgencyGrant
Emergence IncubatorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2021

    $40K grant received from Atlantic Canada Opportunities Agency.

Remidose Aerosols Inc. Filings

Explore SEC and related filing metadata, where available.

Remidose Aerosols Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Remidose Aerosols Inc.'s valuation, stock price, and market status.

Is Remidose Aerosols Inc. a public or private company?

Remidose Aerosols Inc. is a private company.

What is the current stock price of Remidose Aerosols Inc.?

Remidose Aerosols Inc. is a private company with no public stock price. Caplight tracks Remidose Aerosols Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Remidose Aerosols Inc. worth (valuation)?

Valuation information for Remidose Aerosols Inc. is not publicly available.

Can I buy Remidose Aerosols Inc. stock?

Remidose Aerosols Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Remidose Aerosols Inc.'s last funding round?

Remidose Aerosols Inc.'s most recent funding round was Accelerator on August 27, 2021.

Who are the main investors in Remidose Aerosols Inc.?

Key investors in Remidose Aerosols Inc. include Atlantic Canada Opportunities Agency, Emergence Incubator.

Will Remidose Aerosols Inc. IPO soon?

No public IPO plans have been announced for Remidose Aerosols Inc..

How can I track Remidose Aerosols Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Remidose Aerosols Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStratford
Year Founded2020
Last FundingAug 27, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?